| Objective To study the effect of oral administration of Jintiange capsule on bone mineral density, bone metabolism and sclerostin in elderly patients with hypertension and osteoporosis. Methods From July 2013 to September 2015, 144 elderly patients with hypertension and osteoporosis were randomly divided into treatment group (n=72) and control group (n=72). The patients in the treatment group were treated with Jintiange capsule + calcium and the control group received calcium only. Serum levels of osteocalcin (OC), serum type I collagen C-terminal peptide (s-CTX), serum bone-derived alkaline phosphatase (BAP), serum osteogenic alkaline phosphatase (BAP), serum sclerostin (SCL) and bone mineral density [lumbar spine anteroposterior, femoral neck, femur trochanter and forearm] were measured at baseline and 12 months after treatment. Results At baseline, there were no significant differences between the two groups in bone mineral density, bone metabolic index and SCL (P> 0.05). After 12 months of treatment, the levels of OC, BAP and BMD of lumbar spine, femoral neck, femur trochanter and forearm increased significantly, and the levels of s-CTX and SCL decreased significantly in both groups (P<0.05), with the improvements in OC, BAP, s-CTX, SCL and BMD of lumbar spine, femoral neck, forearm and femur significantly better in the Jintiange capsule + calcium group compared with the control group (P<0.05). Conclusion Oral Jintiange Capsule improves bone mineral density in patients with hypertension by influencing bone metabolism and suppressing SCL expression. |